For the current week, the overall ratings of three Biotechnology stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Synergy Pharmaceuticals (NASDAQ:SGYP) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. SGYP also rates an F in Portfolio Grader’s specific subcategory of Equity. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Ironwood Pharmaceuticals (NASDAQ:IRWD) gets weaker ratings this week as last week’s C drops to a D. Ironwood Pharmaceuticals discovers, develops, manufactures, and commercializes marketed drugs. The stock gets F’s in Equity and Cash Flow. 

For a full analysis of IRWD stock, visit Portfolio Grader.

Opko Health (NYSE:OPK) earns a D this week, moving down from last week’s grade of C. OPKO Health is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. The stock also gets an F in Equity. As of Sept. 12, 10.5% of outstanding Opko Health shares were held short. To get an in-depth look at OPK, get Portfolio Grader’s complete analysis of OPK stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.